T1	PROC 44 75	Estudio maestro de continuación
T2	LIVB 79 88	pacientes
#1	AnnotatorNotes T2	C0030705; Patients; Patient or Disabled Group
T3	PROC 113 133	estudio en oncología
T4	CHEM 145 155	Durvalumab
#2	AnnotatorNotes T4	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T5	PROC 184 215	Estudio maestro de continuación
T6	LIVB 219 228	pacientes
#3	AnnotatorNotes T6	C0030705; Patients; Patient or Disabled Group
T7	PROC 253 273	estudio en oncología
T8	CHEM 281 291	Durvalumab
#4	AnnotatorNotes T8	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T9	LIVB 301 313	investigador
#5	AnnotatorNotes T9	C0035173; Research Personnel; Professional or Occupational Group
T10	PROC 363 387	continuar el tratamiento
T11	DISO 409 461	Carcinoma urotelial y no urotelial de vías urinarias
T12	Neg_cue 431 433	no
T13	Negated 434 443	urotelial
T14	Date 462 478	posquimioterapia
T15	LIVB 479 488	Pacientes
#6	AnnotatorNotes T15	C0030705; Patients; Patient or Disabled Group
T16	DISO 510 546	cáncer de pulmón de células pequeñas
#7	AnnotatorNotes T16	C0149925; Small cell carcinoma of lung; Neoplastic Process
T17	DISO 548 552	CPCP
#8	AnnotatorNotes T17	C0149925; Small cell carcinoma of lung; Neoplastic Process
T18	DISO 558 568	enfermedad
#9	AnnotatorNotes T18	C0012634; Disease; Disease or Syndrome | C0221423; Illness (finding); Sign or Symptom
T19	DISO 587 649	Cáncer de pulmón de células no pequeñas avanzado o metastásico
#10	AnnotatorNotes T19	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T20	Neg_cue 615 617	no
T21	Negated 618 626	pequeñas
T22	LIVB 653 662	pacientes
#11	AnnotatorNotes T22	C0030705; Patients; Patient or Disabled Group
T23	Neg_cue 663 666	sin
T24	PROC 667 678	tratamiento
#12	AnnotatorNotes T24	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T25	Negated 667 678	tratamiento
T26	CHEM 690 735	receptor del factor de crecimiento epidérmico
#13	AnnotatorNotes T26	C1739039; EGFR protein, human; Amino Acid, Peptide, or Protein · Receptor
T27	Negated 690 735	receptor del factor de crecimiento epidérmico
T28	CHEM 737 741	EGFR
#14	AnnotatorNotes T28	C1739039; EGFR protein, human; Amino Acid, Peptide, or Protein · Receptor
T29	Negated 737 741	EGFR
T30	DISO 745 762	patología tumoral
T31	LIVB 766 770	cepa
T32	CHEM 784 813	quinasa de linfoma anaplásico
T33	CHEM 815 818	ALK
#15	AnnotatorNotes T33	C1663627; ALK protein, human; Amino Acid, Peptide, or Protein · Enzyme · Receptor
T34	DISO 821 894	Cáncer de pulmón de células no pequeñas no resecable, localmente avanzado
#16	AnnotatorNotes T34	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T35	Neg_cue 849 851	no
T36	Negated 852 860	pequeñas
T37	Neg_cue 861 863	no
T38	Negated 864 873	resecable
T39	DISO 951 957	cáncer
#17	AnnotatorNotes T39	C0006826; Malignant Neoplasms; Neoplastic Process
T40	PROC 1037 1067	ICF escrito, firmado y fechado
T41	LIVB 1076 1084	paciente
#18	AnnotatorNotes T41	C0030705; Patients; Patient or Disabled Group
T42	Date 1093 1104	actualmente
T43	LIVB 1151 1163	investigador
#19	AnnotatorNotes T43	C0035173; Research Personnel; Professional or Occupational Group
T44	PROC 1169 1189	tratamiento contínuo
T45	CHEM 1235 1250	compuesto de AZ
T46	LIVB 1327 1335	paciente
#20	AnnotatorNotes T46	C0030705; Patients; Patient or Disabled Group
T47	PROC 1367 1378	tratamiento
#21	AnnotatorNotes T47	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T48	DISO 1458 1467	Toxicidad
#22	AnnotatorNotes T48	C0600688; Toxic effect; Injury or Poisoning
T49	Date 1468 1476	en curso
T50	Neg_cue 1478 1480	no
T51	Negated 1481 1489	resuelta
T52	PROC 1529 1557	interrupción del tratamiento
T53	Date 1618 1629	Actualmente
T54	Contraindicated 1638 1653	tratamiento con
T55	PROC 1638 1649	tratamiento
#23	AnnotatorNotes T55	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T56	CHEM 1660 1671	medicamento
#24	AnnotatorNotes T56	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0304228; Proprietary drug, NOS; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T57	Contraindicated 1660 1671	medicamento
T58	PROC 1744 1764	investigación médica
T59	Neg_cue 1769 1771	no
T60	Negated 1785 1820	científica o médicamente compatible
T61	PROC 1843 1855	Interrupción
T62	DISO 1898 1907	toxicidad
#25	AnnotatorNotes T62	C0600688; Toxic effect; Injury or Poisoning
T63	DISO 1910 1937	progresión de la enfermedad
#26	AnnotatorNotes T63	C0242656; Disease Progression; Pathologic Function
T64	CHEM 1958 1970	medicamentos
#27	AnnotatorNotes T64	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0304228; Proprietary drug, NOS; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T65	Neg_cue 1998 2001	sin
T66	Negated 2002 2007	costo
T67	LIVB 2016 2024	paciente
#28	AnnotatorNotes T67	C0030705; Patients; Patient or Disabled Group
T68	DISO 2166 2174	COVID-19
#29	AnnotatorNotes T68	C5203670; COVID19 (disease); Disease or Syndrome
T69	PROC 2191 2194	PCR
#30	AnnotatorNotes T69	C0032520; Polymerase Chain Reaction; Molecular Biology Research Technique | C0201657; C-reactive protein measurement; Laboratory Procedure
T70	Speculated 2199 2211	clínicamente
T71	Spec_cue 2212 2222	sospechado
T72	DISO 2225 2237	tuberculosis
#31	AnnotatorNotes T72	C0041296; Tuberculosis; Disease or Syndrome | C0041327; Tuberculosis, Pulmonary; Disease or Syndrome
T73	DISO 2239 2250	hepatitis B
#32	AnnotatorNotes T73	C0019163; Hepatitis B; Disease or Syndrome
T74	PROC 2283 2288	HBsAg
#33	AnnotatorNotes T74	C0201477; Hepatitis B surface antigen measurement; Laboratory Procedure
T75	DISO 2291 2302	hepatitis C
#34	AnnotatorNotes T75	C0019196; Hepatitis C; Disease or Syndrome
T76	DISO 2305 2308	VIH
#35	AnnotatorNotes T76	C0458074; Human immunodeficiency virus (HIV) status; Finding
T77	PROC 2310 2329	anticuerpos VIH 1/2
T78	LIVB 2346 2378	Pacientes masculinos o femeninos
T79	PHYS 2383 2405	potencial reproductivo
T80	Spec_cue 2383 2392	potencial
T81	Speculated 2393 2405	reproductivo
T82	Neg_cue 2410 2412	no
T83	PROC 2443 2464	método anticonceptivo
#36	AnnotatorNotes T83	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T84	Negated 2443 2464	método anticonceptivo
T85	Negated 2465 2471	eficaz
T86	Duration 2511 2518	90 días
T87	PROC 2549 2560	monoterapia
#37	AnnotatorNotes T87	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T88	CHEM 2565 2575	durvalumab
#38	AnnotatorNotes T88	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T89	DISO 2581 2590	Toxicidad
#39	AnnotatorNotes T89	C0600688; Toxic effect; Injury or Poisoning
T90	Date 2602 2610	en curso
T91	Neg_cue 2612 2614	no
T92	Negated 2615 2623	resuelta
T93	Neg_cue 2629 2640	incapacidad
T94	PROC 2646 2672	reducir el corticosteroide
T95	Negated 2646 2672	reducir el corticosteroide
T96	Dose 2688 2697	</= 10 mg
T97	CHEM 2701 2711	prednisona
#40	AnnotatorNotes T97	C0032952; prednisone; Hormone · Organic Chemical · Pharmacologic Substance
T98	Frequency 2712 2719	por día
T99	Duration 2739 2753	las 12 semanas
T100	PROC 2839 2863	Modificación de la dosis
T101	DISO 2867 2876	toxicidad
#41	AnnotatorNotes T101	C0600688; Toxic effect; Injury or Poisoning
T102	CHEM 2879 2882	TMG
T103	DISO 2901 2974	reacciones inmunológicas, relacionadas con la infusión y no inmunológicas
T104	PROC 2947 2955	infusión
#42	AnnotatorNotes T104	C0574032; Infusion procedures; Therapeutic or Preventive Procedure
T105	Neg_cue 2958 2960	no
T106	Negated 2961 2974	inmunológicas
T107	Date 12 16	2021
T108	PROC 975 992	estudio de origen
T109	PROC 1196 1219	estudio de origen de AZ
T110	PROC 1395 1426	protocolo del estudio de origen
T111	PROC 1595 1612	estudio de origen
T112	PROC 1830 1837	estudio
T113	PROC 1871 1888	estudio de origen
T114	DISO 2138 2147	Infección
T115	PROC 2497 2504	estudio
T116	CHEM 2788 2811	tratamiento del estudio
T117	PROC 2812 2831	régimen del estudio
T118	PROC 2979 2996	estudio de origen
T119	Route 2947 2955	infusión
T120	Observation 334 359	beneficiarse clínicamente
T121	Quantifier_or_Qualifier 569 574	grave
T122	Quantifier_or_Qualifier 576 584	etapa IV
T123	Quantifier_or_Qualifier 618 626	pequeñas
T124	Quantifier_or_Qualifier 627 635	avanzado
T125	Quantifier_or_Qualifier 766 780	cepa silvestre
T126	Quantifier_or_Qualifier 852 860	pequeñas
T127	Quantifier_or_Qualifier 864 873	resecable
T128	Quantifier_or_Qualifier 875 894	localmente avanzado
T129	Quantifier_or_Qualifier 896 906	etapa III)
T130	Observation 1108 1125	beneficio clínico
T131	CONC 1297 1303	detuvo
T132	Observation 1481 1489	resuelta
T133	Quantifier_or_Qualifier 1494 1512	Grado 3 o superior
T134	CONC 1578 1602	finalización del estudio
T135	Observation 1693 1717	inscrito simultáneamente
T136	Quantifier_or_Qualifier 1798 1820	médicamente compatible
T137	CONC 2002 2007	costo
T138	Result_or_Value 2252 2270	resultado positivo
T139	Result_or_Value 2330 2339	positivos
T140	Quantifier_or_Qualifier 2393 2405	reproductivo
T141	Observation 2419 2429	dispuestos
T142	Quantifier_or_Qualifier 2465 2471	eficaz
T143	CONC 2481 2490	inclusión
T144	CONC 2533 2545	última dosis
T145	Quantifier_or_Qualifier 2594 2601	grado 2
T146	Observation 2615 2623	resuelta
T147	CONC 2771 2783	última dosis
T148	Quantifier_or_Qualifier 2961 2974	inmunológicas
T149	Patient 79 88	pacientes
T150	History_of 113 133	estudio en oncología
T151	History_of 145 155	Durvalumab
T152	Patient 219 228	pacientes
T153	History_of 253 273	estudio en oncología
T154	History_of 281 291	Durvalumab
T155	Other 301 313	investigador
T156	Patient 479 505	Pacientes de primera línea
T157	Patient 653 662	pacientes
T158	History_of 667 678	tratamiento
T159	History_of 690 741	receptor del factor de crecimiento epidérmico (EGFR
T160	Patient 1076 1084	paciente
T161	Other 1151 1163	investigador
T162	Patient 1327 1335	paciente
T163	Patient 2016 2024	paciente
T164	Patient 2346 2378	Pacientes masculinos o femeninos
T165	History_of 2549 2560	monoterapia
T166	History_of 2565 2575	durvalumab
